


MICIS



Maine Independent Clinical Information Service




Maine Medical Association



ODU & MAR:

Caring for Our Communities

MICIS



Maine Independent Clinical Information Service



Maine Medical Association



Speaker:
Elisabeth Fowlie Mock, MD, MPH

Disclosures

- MICIS does not accept any money from pharmaceutical companies
- Speakers and planners have no significant or relevant financial relationships to disclose
- This presentation includes “off label use” of medications

Objectives

At the conclusion of the MICIS learning session, the learner will have the ability to:

1. Appropriately recognize, diagnose and talk about opioid use disorder (OUD)
2. Compare pharmacologic treatments used in Medication Assisted Recovery (MAR)
3. Develop a strategy for treating acute pain for patients with OUD
4. Constantly consider harm reduction

Handout Materials May Include

- “un-ad” or one page handout
- How to Use Naloxone (pt brochure)
- Evidence & Resource document at MICISMAINE.org

Opioid Use Disorder is a Chronic Disease

typically, a chronic, relapsing, yet treatable illness; associated with significantly increased rates of morbidity and mortality

(Strain, 2018)

**LIKE MANY CHRONIC DISEASES,
OUD HAS ITS ORIGINS IN
ADOLESCENCE**

Use in Adolescence

- 9 of 10 people with addiction started smoking, drinking or using drugs before age 18
- The earlier the substance use, the greater the likelihood of addiction
- Average age of first use 13-14 years

High School Students— EtOH, Tobacco & Drugs

- 75% have used 1 or > substances
- ~50% are current users
- 12.5% meet diagnostic criteria for addiction

Reframing social norms:

**YOUTH SUBSTANCE USE IS A
HEALTH THREAT RATHER THAN A
NORMAL RITE OF PASSAGE**

Reducing Risk


- Delay all substance use for as long as possible
- Be vigilant for signs of risk
- Intervene appropriately

Substance use is changing our demographics

**U.S. life expectancy declined for
3 years in a row (2014-2017), largely
because of unintentional injuries
(includes unintentional OD).**

*(NCHS Data Brief No. 293, 2016;
NCHS Data Brief No. 328, 2018)*

3 Waves of the Rise in Opioid Overdose Deaths




Wave 1: Rise in Prescription Opioid Overdose Deaths

Wave 2: Rise in Heroin Overdose Deaths

Wave 3: Rise in Synthetic Opioid Overdose Deaths

Maine Overdose Deaths



2018 overdoses involving opioids: **80%**

2018 OD Deaths by County

- Waiting for final report from Atty General's office

Opioid-related ED Visits

July 2016 – Sept 2017

- Increase of 34% in Maine
- Massachusetts, New Hampshire, Rhode Island had 'nonsignificant' decreases (<10%)

(Vivolo-Kantor, 2018)

There are several studies that demonstrate the negative impact of using demeaning, pejorative, or stigmatizing language — such language doesn't just hurt feelings — the research shows that when such language is used people are less likely to get the medical care they so desperately need.

- Omar Manejwala, MD, Addiction Specialist

ODU/MAR Debate

We Need to Be Prepared to Recognize and Treat OUD

And how we talk about it MATTERS

DSM-5 Criteria for Opioid Use Disorder

A problematic pattern of opioid use leading to clinically significant impairment or distress, as manifested by at least two of the following, occurring within a 12-month period:

- Mild: 2-3 criteria
- Moderate: 4-5 criteria
- Severe: ≥ 6 criteria

DSM-5 Criteria for Opioid Use Disorder

- Opioids are often taken in **larger amounts** or over a **longer period** than was intended.
- There is a persistent **desire** or unsuccessful efforts **to cut down** or control opioid use.
- A great deal of **time is spent** in activities necessary to **obtain** the opioid, **use** the opioid, or **recover** from its effects.
- **Craving**, or a strong desire or urge to use opioids.

DSM-5 Criteria for Opioid Use Disorder

- Recurrent opioid use resulting in a **failure to fulfill** major **role obligations** at work, school, or home.
- Continued opioid use despite having **persistent or recurrent social or interpersonal problems** caused or exacerbated by the effects of opioids.
- **Important** social, occupational, or recreational **activities** are **given up** or reduced because of opioid use.
- Recurrent opioid **use** in situations in which it is **physically hazardous**.

DSM-5 Criteria for Opioid Use Disorder

- Continued opioid use despite knowledge of having a **persistent or recurrent physical or psychological problem** that is likely to have been caused or exacerbated by the substance.
- **Tolerance,*** need for markedly increased amounts of opioids to achieve intoxication/desired effect or markedly diminished effect with continued use of the same amount of an opioid.
- **Withdrawal,*** characteristic opioid withdrawal syndrome or opioids are taken to relieve or avoid withdrawal symptoms.

*Criteria are not applied to individuals taking opioids by prescription as most on chronic, higher doses have tolerance and withdrawal.

RECOVERY

Guiding Principles of Recovery

- ❖ a process of change
- ❖ improving health and wellness
- ❖ living a self-directed life
- ❖ striving to reach full potential
- ❖ no “one size fits all” approach



(SAMSHA, 2012)

Four Dimensions that Support a Life in Recovery

Health

Home

Purpose

Community

(SAMSHA website)

MAR: Effective, Cost-effective, and Cost-beneficial

Medications:

- reduce illicit opioid use
- retain people in treatment
- reduce risk of opioid overdose death
- better than treatment with placebo or no medication

Who Can Prescribe or Dispense?

- Buprenorphine
- Methadone
- Emergency methadone or buprenorphine (72h)
- Naltrexone

Newer Buprenorphine Formulations

- subdermal implant (6 months)
- injection (monthly)

Naltrexone

- Initiation of naltrexone must be preceded by withdrawal from opioids (preferably medically supervised);
- oral naltrexone has higher dropout rates than injectable.

Recovery Occurs via Many Pathways

- one year recovery rates:
 - 50% with medication-assistance,
 - 10% without medication

(multiple sources cited in references)

Which Patients Are Best Suited for tx in Primary Care Settings?

Which Patients Are Best Suited for tx in Primary Care Settings?


- stable/controlled medical comorbidities
- stable/controlled psychiatric comorbidities
- safe, substance-free living environment

Which Patients Are Best Suited for tx in “HUBS”?

- continued opioid use despite bup tx
- poor response to bup
- previous misuse or diversion of bup
- poorly controlled psychiatric illness
- co-morbid SUD (especially severe BZDP/EtOH use)

Hub & Spokes Collaborate

Hubs




High intensity MAT


Methadone, buprenorphine,
naltrexone

Regional locations

All staff specialize in addictions
treatment



Spokes



Maintenance MAT


Buprenorphine, naltrexone

Community locations


Lead provider + nurse and
LADC/MA counselor

National Buprenorphine Data


2% of all prescribers have an x-waiver




~50% of those ever prescribe



~50% of those prescribe 1-4 patients



Maine Buprenorphine Prescribers



How long to treat?

Indefinite. No evidence base. Patients:

- may stay on medium doses (~8-16)
- may slowly taper and wean after a few years of stability
- remain on low dose therapy long-term
- may go on and off treatment

Acute Pain in Patients with OUD

Baseline opioid maintenance therapies are not adequate for pain control in patients with acute, moderate to severe injuries and surgeries beyond minor procedures.

In Patients on Methadone and Buprenorphine:

- verify the dose
- maximize nonopioid pain treatments
(pharmacologic and nonpharmacologic)
- consider increasing or splitting dose
- add higher dose short-acting opioids for
3-5d

Actively using heroin/other opioid:

- try to get a history of 'dose'
- maximize non-opioid modalities
- consider tramadol
- always try to use oral medications in preference over IV
- consider increased doses post-operatively
- avoid take-home prescriptions in most cases

In Patients on Naltrexone:

- try to delay elective interventions
- maximize nonopioid pain treatments
(pharmacologic and nonpharmacologic)
- if emergency may need higher than usual doses of opioids to overcome—high risk of respiratory depression

Contact recovery medication prescriber proactively or as soon as possible in unscheduled/emergent situations to discuss acute pain needs, taper schedule, and who will handle prescribing

Hardwire Harm Reduction Strategies in All Medical Practices

SAVE LIVES FIRST

(Harm Reduction)

Social Determinants of Health Contribute to the Opioid Epidemic

Homeless persons were **9x** more likely to die from OD than persons stably housed.

A “housing first” approach to recovery increases likelihood of success.

Social Determinants of Health Contribute to the Opioid Epidemic

Persons who are released from incarceration

*are at a **12**x risk of overdose.*

Jails/prisons in Maine

will provide MAR soon.

Harm Reduction

- Prescribe opioids using conservative management strategies
- Limit supplies to 3-5 days for acute pain
- Avoid co-prescribing with BZDP
- Exhaust nonopioid and nonpharmacologic treatment strategies (for acute or chronic)
- Document informed consent

Consider Naloxone Prescriptions for:

- all patients on chronic opioids, especially at doses over 50 MME
- any patient co-prescribed benzodiazepines/sedatives or actively using alcohol
- friends or family members who might witness overdose
- patients with OUD being released from incarceration or treatment programs
- patients with history of overdose
- patients with underlying respiratory disease, especially sleep apnea
- all patients in MAR

*“Use of marijuana, stimulants, or other addictive drugs should not be a reason to suspend OUD tx. However, evidence demonstrates pts actively using substances during OUD tx have a poorer prognosis. The use of EtOH, bzdp and other sedative hypnotics may be a reason to ~~suspend~~ **adjust** agonist tx—safety concerns related to respiratory depression.”*

In Summary...

- The words you use to describe OUD and an individual with OUD are powerful
- Recovery is possible and more likely when using medications combined with counselling
- OUD medications reduce illicit opioid use, reduce overdose deaths, decrease crime and retain people in treatment/counselling
- Treat acute pain with multiple modalities for all patients, including those in recovery
- Recommend naloxone prescriptions for all patients in recovery

QC MAR Resources

- <https://mainequalitycounts.org/what-we-do/population-health/naloxone-and-mat-resources/>

Peter Leighton video updates

- Filmed early 2017
- OD numbers are 2016
- Our understanding of the types of counselling and peer support most effective for achieving recovery continues to evolve
- As of 4/17: NPs & PAs can get independent buprenorphine waivers (24 hour course)

Video Resources

➤ Diversion Alert/recoveryinme video

- www.youtube.com/watch?v=q1ISmWWwM40

➤ CDC Videos

- www.cdc.gov/rxawareness/resources/video.html

RX Awareness Campaign Trailer (1:53) & Brenda's Rx Awareness Story (0:30)

➤ Peter Leighton MAT recruitment

- www.youtube.com/watch?v=WjtYp_pMUqI (trailer)
- www.youtube.com/watch?v=3pT_BJtsraA&feature=youtu.be (full length)

MICISTravels on facebook
references: MICISMaine.org

SLIDE PARKING LOT

The words you use to describe OUD and an individual with OUD are powerful. Providers should adopt terminology that will not reinforce prejudice, negative attitudes, or discrimination.

- Omar Manejwala, MD, Addiction Specialist

Counselors help clients by...

addressing the challenges &
consequences of OUD

Words are important. If you want to care for something, you call it a 'flower'; if you want to kill something, you call it a 'weed'.

- Don Coyhis, Native American Recovery coach

Bias may be a Barrier

Emergency physicians at Hopkins had lower regard for pts with SUDs than other medical conditions with behavioral components.

54% at least “somewhat agree” that they prefer not to work pts with SUD who have pain